TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 20 to 45, healthy male subjects(at screening)~* Body weight between 55kg - 90kg, BMI between 18.0 - 27.0~* FPG 70-125mg/dL glucose level(at screening)~* Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.~Exclusion Criteria:~* Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)~* Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)~* Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)~* Subject who already participated in other trials in 2months~* Subject who had whole blood donation in 2months, or component blood donation in 1months or transfusion in 1months currently.~* Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LC15-0444 (Type: EXPERIMENTAL): LC15-0444 50mg qd
- Metformin (Type: EXPERIMENTAL): Metformin 1000mg bid
- LC15-0444+Metformin (Type: EXPERIMENTAL): LC15-0444 50mg qd +Metformin 1000mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has genetic confirmation of primary hyperoxaluria type 1 (PH1)~* Meets urinary oxalate excretion requirements~* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days~Exclusion Criteria:~* If \<12 months old at screening, has an abnormally high serum creatinine~* If ≥12 months old at screening, has an estimated glomerular filtration rate (GFR) of ≤45 mL/min/1.73m\^2~* Clinical evidence of systemic oxalosis~* History of kidney or liver transplant

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Lumasiran (Type: EXPERIMENTAL): Lumasiran will be administered by subcutaneous (SC) injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Prophylactic Steroids in the Prevention of Post-thyroidectomy Hypocalcaemia and Voice Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Benign thyroid condition.~* Patients without any preoperative corrected hypocalcaemia and voice or vocal quality dysfunction.~Exclusion Criteria:~* Previous thyroid or neck surgery~* Known vocal cord dysfunction on laryngoscopy~* Hearing or voice problems~* History of gastroesophageal reflux and stomach ulcer disease~* Contraindications of steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
- Placebo (Type: PLACEBO_COMPARATOR): Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine-Associated Psychosis.~2. Must sign a Information consent form.~3. Required to provide detailed address and phone number~Exclusion Criteria:~1. Serious organic disease.~2. Suicide ideation or hurt others.~3. Taking antipsychotic within two weeks before.~4. drug allergy to Risperidone or paliperidone.~5. pregnancy and breastfeeding women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- paliperidone (Type: EXPERIMENTAL): paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
- .Risperidone (Type: ACTIVE_COMPARATOR): Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed six months of maintenance treatment in the SP512 double-blind trial~Exclusion Criteria:~* Subjects who had an ongoing serious adverse event from SP512 double-blind trial that was assessed as related to study medication

- Gender: ALL
- Minimum Age: 31 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be enrolled into the 2-week placebo run-in period if they meet all the following criteria:~* Age ≥ 1 year and ≤ 4 years.~* At least 3 episodes of wheeze or asthma-like symptoms in the 6 months preceding the study entry.~* A cooperative attitude and ability to be trained to inhale correctly from the device and to complete the diary cards.~* Written parental/guardian informed consent obtained.~Patients will be then randomised to the treatment period if they meet all the previous criteria plus:~* Presence in at least 7 days out of the 14 days of the run-in period of at least one of the following symptoms: wheeze, cough or shortness of breath; or had required at least one dose of relief salbutamol.~Exclusion Criteria:~* History of severe asthma exacerbation or exacerbations requiring hospitalisation in the previous 4 weeks.~* Symptomatic infection of the airways requiring treatment with antibiotics or antimycotics in the previous 4 weeks.~* Treatment with inhaled steroids in the previous 4 weeks or oral steroids in the previous 8 weeks.~* Treatment with methyl-xantine derivatives in the previous 4 weeks.~* Treatment with long-acting β2-agonists in the previous 2 weeks.~* Changes in asthma medications taken on regular basis in the previous 4 weeks.~* Symptoms of asthma limited to seasonal allergen exposure.~* History of clinically significant cardiac, renal, neurologic, hepatic, endocrine or pulmonary disease (except asthma), or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results of the present study.~* Evidence of pulmonary malformations.~* Evidence of immunological deficiency (patients to be withdrawn if diagnosed during the study).~* Cancer or any other chronic disease with prognosis \< 2 years.~* Hypersensitivity to inhaled corticosteroids.~* Participation in another trial in the last 4 weeks.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Beclomethasone dipropionate (Type: EXPERIMENTAL): None
- Beclomethasone dipropionate/Salbutamol combination (Type: EXPERIMENTAL): None
- Salbutamol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Periodontal Therapy on Patients With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be able to understand the informed consent form and be willing and able to read and sign it.~2. At least 25 years of age.~3. Be able to understand and follow directions for study procedures.~4. At least 14 natural teeth, not counting third molars (wisdom teeth).~5. At least 2 interproximal sites with CAL \>= 4 mm or at least 2 interproximal sites with PD \>= 5 mm.~Exclusion Criteria:~1. Presence of orthodontic appliances (braces).~2. An abnormal condition of lips, lining of the mouth, tongue, or gums (except for periodontal disease). If subject has a cold sore, canker sore, or injury in their mouth, they may return after the sore or injury heals.~3. Abscess of the gingiva caused by periodontal disease, or visible gross tooth decay~4. A broken tooth root or an abscessed tooth. Subject may be allowed to participate in the study after the condition is successfully treated.~5. Periodontal treatment or antibiotic therapy in the past 6 months.~6. Have used cigarettes or other tobacco products in the past year.~7. Body mass index (BMI) is \> 40.~8. Have regularly used non-steroidal anti-inflammatory drugs (such as \>= 325 mg aspirin or ibuprofen) over the past 3 weeks.~9. Regularly using drugs that weaken the immune system (such as corticosteroids taken by mouth or injection, and cyclosporine).~10. Have participated in another clinical research study in the past 30 days.~11. Pregnant or breastfeeding.~12. Have a condition that we feel will make study participation unsafe or difficult for the patient.~13. Require premedication for dental exams.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Diabetic + SRP + SPT (Type: EXPERIMENTAL): The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling \& root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
- B: Non-Diabetic + SRP + SPT (Type: EXPERIMENTAL): The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling \& root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
- C: Diabetic + SRP (Type: ACTIVE_COMPARATOR): The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
- D: Non-Diabetic + SRP (Type: ACTIVE_COMPARATOR): The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Cervical Dystonia at least 9 months since onset and either previously untreated with botulinum toxin or currently treated with Botox at a total dosing range of 100-200 U and ≤60 U in the sternocleidomastoid muscle at the last injection cycle, and having had a satisfactory treatment response in the principal investigator's judgment during the last two sequential Botox treatment cycles.~* TWSTRS total score≥ 20; TWSTRS-severity subscale score\> 10;~Exclusion Criteria:~* In apparent remission from Cervical Dystonia~* Diagnosis of pure retrocollis or pure anterocollis~* For non-naïve subjects, previous poor response to either of the last two Botox treatments~* Known requirement of \<100U or \>200U of Botox injected into the neck muscles

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport® (Type: ACTIVE_COMPARATOR): Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, up to 2mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of i/t Curve in Assessment of Phototherapy Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria included: informed consent, good tolerance of current pulses, completion of all phototherapy sessions, declaration of alcohol/drugs/smoking abstinence~The exclusion criteria were: acute inflammatory processes and fever, the presence of pigmented moles in the irradiated area, exposure to any other physical factors, a history of upper limb trauma, and upper limb overload.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- Piler light + red filter (Type: ACTIVE_COMPARATOR): Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
- Piler light + blue filter (Type: ACTIVE_COMPARATOR): Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
- Piler light without a filter (Type: ACTIVE_COMPARATOR): Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
- placebo (Type: PLACEBO_COMPARATOR): Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or metastatic breast cancer Bidimensionally measurable disease No bone scan abnormalities alone Lytic lesions allowed in conjunction with bone scan abnormalities No pure blastic bone metastases No pleural or peritoneal effusions No previously irradiated lesions Resected disease not allowed No brain metastases or leptomeningeal disease Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1500/mm3 Hemoglobin at least 8.0 g/dL Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 2.0 mg/dL Calcium no greater than 11.0 mg/dL Cardiovascular: No history of arrhythmias No history of other significant cardiac diseases No New York Heart Association class III or IV cardiac function Left ventricular ejection fraction at least 50% Pulmonary: No symptomatic lymphangitic pulmonary metastases Other: Not pregnant Negative pregnancy test No history of other malignancy except: Carcinoma in situ of the cervix Curatively treated nonmelanoma skin cancer No severe infection No severe malnutrition No other serious medical illness No history of grade 3-4 peripheral neuropathy~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered No more than 3 prior chemotherapy regimens as adjuvant/neoadjuvant therapy or for disease At least 1 year since prior paclitaxel or docetaxel Prior anthracycline (doxorubicin or epirubicin) or mitoxantrone-based regimen allowed as adjuvant therapy or for advanced disease No other concurrent chemotherapy Endocrine therapy: At least 3 weeks since prior exogenous hormonal therapy for stage IV disease and/or as adjuvant therapy Radiotherapy: No radiotherapy to greater than 50% of marrow At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherepy to the only measurable lesion Surgery: At least 2-3 weeks since prior surgery and recovered No concurrent surgery to the only measurable lesion Other: No concurrent nonprotocol treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smokes ≥5 cigarettes per day~* Born outside the U.S.~* Interested in receiving smoking and financial counseling~* Self-reported income below 200% of the current federal poverty level for a given household composition~* New York City resident~* English or Spanish language~* Able to provide informed consent, and~* Does not have a representative who manages his/her funds (to ensure the participant has the ability to manage household money). We will exclude participants who report being pregnant or breastfeeding (unable to receive NRT).~Hospital staff participants:~* Must be current medical or non-medical provider or administrator at Bellevue Hospital or New York University Lutheran Medical Center~Exclusion Criteria:~* We will exclude participants who report being pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: ACTIVE_COMPARATOR): None
- Waitlist Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusions for PTSD and Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female veterans aged 18 to 75 years.~* Participants must have a telephone in their home and ability to hear telephone conversations.~* Participants must meet current DSM-IV criteria for major depressive disorder (MDD), single or recurrent, without psychotic features~* Participants must meet DSM-5 criteria for current post-traumatic stress disorder (PTSD) and have received a diagnosis of PTSD greater than or equal to 3 months prior to assessment.~* Current major depressive episode resistant to treatment.~* If applicable, current antidepressant dosages including augmenting agents and/or frequency and duration of psychotherapy sessions must remain stable for at least 6 weeks prior to beginning of the study.~Exclusion Criteria:~* Inability to speak English~* Inability or unwillingness to provide written informed consent~* Moderate/severe cognitive impairment .~* Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition.~* Current or lifetime diagnosis of a Cluster B disorder.~* History of moderate or severe traumatic brain injury, Parkinson's disease, dementia of any type, multiple sclerosis, seizures or other CNS related disorders.~* History of comorbid substance disorder within 6 months of screening as assessed using the Mini International Neuropsychiatric Interview (MINI), plus positive urine toxicology screen test during baseline assessments.~* Prior use of ketamine as an antidepressant.~* Clinically unstable medical illness that could compromise the patient's ability to tolerate or likely interfere with the study procedures (e.g., history of or current myocardial ischemia or arrhythmias, congestive heart failure, severe pulmonary, renal, or hepatic disease, uncontrolled hypertension)~* Current or within less than 14 days use of barbiturates or monoamine oxidase inhibitors (MAOI).~* History of antidepressant- or substance-induced hypomania.~* History of first degree relative(s) with an Axis I psychotic disorder.~* For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study.~* Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Six ketamine infusions (Type: EXPERIMENTAL): Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete